Advisors Preferred’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Advisors Preferred’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,029	Closed	-$105K	–	224
2017 Q3	$105K	Buy	+1,029	New	+$89.9K	0.06%	103
2017 Q2	–	Sell	-253	Closed	-$22	–	229
2017 Q1	$22	Buy	+253	New	+$18.2K	0.01%	163
2016 Q4	–	Sell	-2,019	Closed	-$131K	–	225
2016 Q3	$131K	Buy	+2,019	New	+$114K	0.06%	109

Other funds holding LKFT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Advisors Preferred's LKFT Position: Q4 2017 in Review

Advisors Preferred sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2017, closing a stake of 1,029 shares — an estimated $105K sold.

Advisors Preferred first reported a position in LKFT in Q3 2016 and held it in 3 quarters. The position peaked at $131K in Q3 2016. 77 funds tracked by Wall St. Rank hold LKFT as of Q4 2017.

Advisors Preferred reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2017 after selling out during the quarter.
Advisors Preferred sold 1,029 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2017, an estimated $105K.
Advisors Preferred first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2016 and held it in 3 quarters.
Advisors Preferred's Lakefront Biotherapeutics American Depositary Shares position peaked at $131K in Q3 2016.
77 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2017.

Based on Advisors Preferred's 13F filing for Q4 2017, filed 12 Feb 2018.